Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	18.73B
Revenue (ttm)	2.40B
Net Income (ttm)	49.24M
Shares Out	1.60B
EPS (ttm)	0.03
PE Ratio	380.31
Forward PE	53.84
Dividend	0.01 (0.09%)
Ex-Dividend Date	May 28, 2025

Volume	18,120,930
Average Volume	37,320,015
Open	11.67
Previous Close	11.67
Day's Range	11.51 - 11.73
52-Week Range	9.70 - 15.12
Beta	0.44
RSI	39.98
Earnings Date	Apr 9, 2026

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.